Tis 7 dec / År 39 / Nr 4 2021

Life Science 2021

The task of developing the healthcare systems, technology and treatments of the future requires a much sharper focus on facilitating collaboration across borders. Not only geographical – but across disciplines as well. Gothenburg has a strong and growing Life Science cluster which deserves to be highlighted from a national point of view.

Take the fast lane to preclinical research and development

Redoxis is a full-service CRO with core competence in preclinical drug development and efficacy evaluation in inflammatory, autoimmune and neurodegenerative disease models. From its head office in Medicon Village in Lund, southern Sweden, Redoxis reaches a global market.

Malin Hultqvist Hopkins, CEO of Redoxis.

Redoxis initially stems from academic research and still has strong collaborations with the academic world. New innovations are often born in academia but taken further by industry. This also describes Redoxis’ own evaluation from research and development spin-off to a full-service contract research organisation.

Wide range of services

Redoxis provides preclinical in vivo and in vitro models, including in vivo efficacy, functional assays, mechanism of action (MoA) evaluation, ex vivo ranking, pharmacokinetic (PK) investigation, biomarker identification and biomarker analyses. Services also include possibility for in vivo imaging in models of relevance for autoimmune diseases, in collaboration with external partners.

“At Redoxis we have a portfolio of standard models but can also find solutions for specific customer requests. What makes us unique is that we are flexible and agile, even when developing entirely new research methods and models for our customers. We provide reliable results from custom-made studies that bring value to our customers’ preclinical programs”, states Malin Hultqvist Hopkins, CEO of Redoxis.

Large customer base

International companies striving to target the Scandinavian and European market often contract Redoxis to perform all stages of preclinical studies in inflammatory and autoimmune diseases. In later years Redoxis has embarked on a new path offering preclinical development services in neurodegenerative disease as well.

There is no specific type of client for us, we strive to serve all companies and academic researchers who need support in the preclinical stages with the same dedication. Our customers can be large pharmaceutical companies or small biotech developers. They can also be part of a research team at a university”, explains Malin Hultqvist Hopkins.

Working closely with academia

Redoxis evolved from ideas from the academic world and has retained its partnerships with academia through the years. Today, Redoxis is often involved in academic research projects, always looking to expand the company’s services and core competence. “Working in research projects funded by the European Union provides an exciting opportunity for continuous development here at Redoxis. This also makes us an interesting employer who can offer projects with both academic and industrial partners.”, says Malin Hultqvist Hopkins.